Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M607Revenue $M55.5Net Margin (%)-50.6Altman Z-Score-1.1
Enterprise Value $M503EPS $-0.3Operating Margin %-38.7Piotroski F-Score6
P/E(ttm)--Beneish M-Score10.5Pre-tax Margin (%)-50.6Higher ROA y-yY
Price/Book48.510-y EBITDA Growth Rate %-26.9Quick Ratio7.5Cash flow > EarningsY
Price/Sales10.05-y EBITDA Growth Rate %-23.2Current Ratio7.6Lower Leverage y-yY
Price/Free Cash Flow21.2y-y EBITDA Growth Rate %--ROA % (ttm)-17.3Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-204.9Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M125ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with OREX

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
Current Price Change from Average Comment Current Shares
OREXGeorge Soros 2012-06-30 Sold Out -0.03%$3.16 - $6.37
$ 4.8529%Sold Out0
OREXGeorge Soros 2012-03-31 Buy 0.03%$1.68 - $5.01
$ 4.8556%New holding500,000
OREXFirst Eagle Investment 2010-09-30 Sold Out -0.01%$3.9 - $6.77
$ 4.85-3%Sold Out0
OREXFirst Eagle Investment 2010-06-30 Add$4.05 - $7.04
$ 4.85-13%Add 74.07%470,000
OREXFirst Eagle Investment 2010-03-31 Add$5.9 - $7.66
$ 4.85-26%Add 22.73%270,000
OREXFirst Eagle Investment 2009-12-31 Add0.01%$6.44 - $9.39
$ 4.85-36%Add 83.33%220,000
OREXFirst Eagle Investment 2009-09-30 Buy 0.01%$5.2 - $10.34
$ 4.85-39%New holding120,000
OREXBill Gates 2009-06-30 Sold Out $1.89 - $5.21
$ 4.8552%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

OREX is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!

OREX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Booth Mark DChief Commercial Officer 2015-02-26Sell50,000$5.68-14.61 view
Turner Heather DSVP, Gen. Counsel & Secretary 2014-12-02Sell22,643$6-19.17 view
Turner Heather DSVP, Gen. Counsel & Secretary 2014-11-25Sell31,388$5.83-16.81 view
BOCK LOUIS CDirector 2014-11-18Buy1,325$5.58-13.08 view
BOCK LOUIS CDirector 2014-11-12Buy27,052$5.57-12.93 view
Turner Heather DVP, Gen. Counsel & Secretary 2014-09-22Sell300,000$4.478.5 view
NARACHI MICHAELPresident and CEO 2014-09-15Buy50,000$4.781.46 view
Hagan Joseph PSr. VP, Corporate Development 2014-09-15Buy5,000$4.693.41 view
Hagan Joseph PChief Business Officer 2013-07-31Sell12,000$7.8-37.82 view
Booth Mark DChief Commercial Officer 2013-07-26Sell64,767$7.55-35.76 view

Press Releases about OREX :

    Quarterly/Annual Reports about OREX:

    News about OREX:

    Articles On GuruFocus.com
    Oxford Industries (OXM) Solid Growth Metrics, Orexigen Therapeutics (OREX) European Anti-Obesity App Mar 27 2015 
    Orexigen Therapeutics' Bright Future Mar 03 2015 
    Revisiting Arena, Orexigen, And VIVUS: Shareholders Can Recoup Their Losses By Invest In MannKind Aug 19 2014 
    Weekly CEO Sells Highlight: Orexigen Therapeutics Inc, Gas Natural Inc, The Middleby Corporation, an Jul 15 2012 
    Weekly CEO Sells Highlight: Gas Natural Inc, Encore Bancshares Inc, Staples Inc, and Orexigen Therap Jul 08 2012 
    Arena Facing Increased Pressure from Peers Apr 23 2012 
    Arena Could Dip If Lorcaserin Fails Again Apr 22 2012 
    Vivus Could Rocket on Success of Qnexa Apr 13 2012 
    Steve Cohen Bets On Orexigen Ahead of FDA Approval Jan 31 2011 
    Orexigen Therapeutics Inc. Reports Operating Results (10-Q) Nov 04 2010 

    More From Other Websites
    OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement May 29 2015
    Orexigen's Rocky Partnership Could End in Disaster May 29 2015
    Zosano Pharma Appoints Joseph P. Hagan to Board of Directors May 27 2015
    Orexigen CEO Pledged To Keep Data Secret, But Not From Himself May 20 2015
    OREXIGEN THERAPEUTICS, INC. Financials May 15 2015
    5 Key Takeaways From Orexigen's Earnings May 14 2015
    Drugmaker’s Very Bad Day Doesn’t Merit a Single Stock Downgrade May 14 2015
    Did Orexigen Have The Right To File Its Controversial Patent? May 14 2015
    OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Other Events May 13 2015
    Macy's and Orexigen are big market movers May 13 2015
    Are Problems at Orexigen Still Just Getting Started? May 13 2015
    Orexigen Slumps as New Contrave Data Comes to Light - Analyst Blog May 13 2015
    Orexigen and Takeda Feud Over Cost of a Controversial Diet Drug Trial May 13 2015
    Biotech Stock Roundup: Alexion to Buy Synageva, FDA Panel Backs Vertex's Orkambi - Analyst Blog May 13 2015
    Orexigen Therapeutics (OREX) Stock Continues to Sink on Contrave Study Fallout May 13 2015
    Tuesday's After-Hours Movers: Vertex Pharmaceuticals, Orexigen Therapeutics And More May 12 2015
    Takeda Threatens to End Orexigen Partnership After Study Halted May 12 2015
    Orexigen Therapeutics Provides Statement on Termination of the Light Study and Updates on Contrave... May 12 2015
    Orexigen Therapeutics Provides Statement on Termination of the Light Study and Updates on Contrave... May 12 2015
    Orexigen Comments On Fallout From Data Release May 12 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)